World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
108
Citations
49509
World Ranking
5944
National Ranking
3180

Overview

Robert L. Coleman is affiliated with The University of Texas MD Anderson Cancer Center in the United States. Their research primarily focuses on medicine, with significant contributions in reproductive medicine, oncology, obstetrics and gynecology, pulmonary and respiratory medicine, and molecular biology. The scientist's work encompasses a range of topics related to cancer diagnosis and treatment, including ovarian cancer diagnosis and treatment, PARP inhibition in cancer therapy, endometrial and cervical cancer treatments, cancer genomics and diagnostics, BRCA gene mutations in cancer, lung cancer treatments and mutations, and toxin mechanisms and immunotoxins.

Selected recent papers authored by Robert L. Coleman include:

  • Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study, 2021, The Lancet Oncology

Frequent coauthors collaborating with Coleman are:

  • Bradley J. Monk
  • David M. O'Malley
  • Kathleen N. Moore
  • Brian M. Slomovitz
  • Shannon N. Westin

The scientist frequently publishes in the following venues:

  • Gynecologic Oncology
  • Journal of Clinical Oncology
  • International Journal of Gynecological Cancer
  • Annals of Oncology
  • Cancer Research

The scope of Coleman's work addresses critical aspects of oncology and gynecologic cancer treatment, contributing to multidisciplinary fields with over 700 publications in medicine-related topics. Their research integrates clinical and translational approaches within reproductive medicine and oncology, with a particularly strong focus on ovarian, endometrial, and cervical cancer therapies. This is reflected in the range of journals and coauthors associated with the scientist.

Best Publications

  • Minimally Invasive versus Abdominal Radical Hysterectomy for Cervical Cancer

    Pedro Tomas Ramirez;Michael Frumovitz;Rene Pareja;Aldo Lopez

  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

    Robert L Coleman;Amit M Oza;Domenica Lorusso;Carol Aghajanian

  • Chronic stress promotes tumor growth and angiogenesis in a mouse model of ovarian carcinoma

    Premal H Thaker;Liz Y Han;Aparna A Kamat;Jesusa M Arevalo

  • Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial

    Elizabeth M Swisher;Kevin K Lin;Amit M Oza;Clare L Scott

  • RNA interference in the clinic: challenges and future directions

    Chad V. Pecot;George A. Calin;Robert L. Coleman;Gabriel Lopez-Berestein

  • Dicer, Drosha, and outcomes in patients with ovarian cancer

    William M. Merritt;Yvonne G. Lin;Liz Y. Han;Aparna A. Kamat

  • Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline ☆

    Alexi A. Wright;Kari Bohlke;Deborah K. Armstrong;Michael A. Bookman

  • Bevacizumab (Avastin®) in cancer treatment: A review of 15 years of clinical experience and future outlook.

    Josep Garcia;Herbert I. Hurwitz;Alan B. Sandler;David Miles

  • Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

    Robert L. Coleman;Gini F. Fleming;Mark F. Brady;Elizabeth M. Swisher

  • Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncology Group study GOG-0213): a multicentre, open-label, randomised, phase 3 trial

    Robert L. Coleman;Mark F. Brady;Thomas J. Herzog;Paul Sabbatini

  • Latest research and treatment of advanced-stage epithelial ovarian cancer

    Robert L. Coleman;Bradley J. Monk;Anil K. Sood;Thomas J. Herzog

  • Preclinical and clinical development of siRNA-based therapeutics

    Gulnihal Ozcan;Bulent Ozpolat;Robert L. Coleman;Anil K. Sood

  • Targeting aldehyde dehydrogenase cancer stem cells in ovarian cancer

    Charles N. Landen;Blake Goodman;Ashwini A. Katre;Adam D. Steg;Adam D. Steg

  • The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer

    Brian M. Slomovitz;Robert L. Coleman

  • Regulation of Tumor Angiogenesis by EZH2

    Chunhua Lu;Hee Dong Han;Lingegowda S. Mangala;Rouba Ali-Fehmi

  • Exploring and comparing adverse events between PARP inhibitors.

    Christopher J LaFargue;Graziela Z Dal Molin;Anil K Sood;Robert L Coleman

  • Selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum: an open-label, single-arm, phase 2 study

    John Farley;William E Brady;Vinod Vathipadiekal;Heather A Lankes

  • Lymphatic Mapping and Sentinel Lymph Node Biopsy in Women With Squamous Cell Carcinoma of the Vulva: A Gynecologic Oncology Group Study

    Charles F. Levenback;Shamshad Ali;Robert L. Coleman;Michael A. Gold

  • Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy

    Jyotsnabaran Halder;Aparna A. Kamat;Charles N. Landen;Liz Y. Han

  • Lymphatic Mapping and Sentinel Node Identification in Patients With Cervix Cancer Undergoing Radical Hysterectomy and Pelvic Lymphadenectomy

    Charles Levenback;Robert L. Coleman;Thomas W. Burke;W. Michael Lin

Frequent Co-Authors

Anil K. Sood
Anil K. Sood The University of Texas MD Anderson Cancer Center
Bradley J. Monk
Bradley J. Monk University of Arizona
Thomas J. Herzog
Thomas J. Herzog University of Cincinnati
David M. O'Malley
David M. O'Malley The Ohio State University
David M. Gershenson
David M. Gershenson The University of Texas MD Anderson Cancer Center
Amit M. Oza
Amit M. Oza Princess Margaret Cancer Centre
Elizabeth M. Swisher
Elizabeth M. Swisher University of Washington
Ana Oaknin
Ana Oaknin Vall d'Hebron Hospital Universitari
Carol Aghajanian
Carol Aghajanian Memorial Sloan Kettering Cancer Center
Pedro Tomas Ramirez
Pedro Tomas Ramirez The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering studying Medicine in the USA, you may also be interested in related online degrees and flexible career pathways within healthcare. The demand for skilled professionals is growing, and online programs can make advanced education more accessible and affordable.

For nursing professionals looking to advance, an online PhD in nursing offers opportunities for research, leadership, and teaching at the highest levels. Those who are already registered nurses but want to complete their bachelor’s degree can explore cheap rn to bsn programs for an affordable, flexible option.

If you have a non-nursing bachelor’s degree but want to transition into nursing, direct entry msn programs can help you fast-track your education and enter the field efficiently. For those interested in accessible training and admissions, it’s worth researching what is the easiest nursing school to get into to find a program that matches your needs and background.

Exploring these online pathways can open doors to rewarding healthcare careers beyond traditional medical school routes.

Best Scientists Citing Robert L. Coleman

Trending Scientists

Recently Published Articles